Cingulate says it has substantially completed the manufacturing work needed to address FDA questions about its ADHD drug candidate CTx-1301 and expects to resubmit the application between December 2026 and January 2027. CEO Shane Schaffer outlined the progress in an interview, alongside the company’s preparations for a potential product launch.
The update concerns a regulatory setback and the path toward resubmission—not an FDA approval. Cingulate says the FDA’s June 2026 response requested additional manufacturing and quality information, but raised no concerns about the drug’s clinical safety or effectiveness.
Key details
-
Drug and indication: CTx-1301, or dexmethylphenidate HCl, is Cingulate’s lead candidate for treating attention deficit/hyperactivity disorder (ADHD).
-
FDA response: The FDA issued a Complete Response Letter on June 1, 2026, after previously setting a May 31, 2026, target action date for its review. The letter requested additional chemistry, manufacturing and controls information.
-
Work toward resubmission: Cingulate says it and its contract manufacturer have substantially completed the manufacturing work needed to address those requests. The company is completing the supporting data and documentation.
-
Expected timing: Cingulate currently expects to resubmit the application between December 2026 and January 2027. The FDA would then classify the resubmission as either Class 1, with a two-month review goal, or Class 2, with a six-month review goal. The classification has not yet been determined.
-
Potential launch: If the FDA approves CTx-1301, Cingulate says a commercial launch could begin in the third quarter of 2027. That timing depends on the resubmission and review process, and approval is not assured.
-
Commercial preparations: Schaffer also discussed the company’s commercialization planning. He and Chief Commercial Officer Bryan Downey recently presented on pharmaceutical commercialization strategies at the Indegene Digital Summit, including what the company calls a “Smart Launch” approach.
What changes for investors
The company’s stated near-term milestone is completing and resubmitting the NDA, rather than resolving a clinical safety or efficacy issue. The projected launch date remains conditional: Cingulate still needs to submit the application, the FDA must accept and review it, and the agency must approve the drug. The company cautions that the resubmission timing, review classification and eventual approval are uncertain.